Replies to post #329885 on ORIONS Money Stocks

[AugustaFriends]

$AEZS Macrilen™
Throughout the remainder of 2014, we expect to continue to advance the pre-launch activities related to the commercialization
of Macrilen™ for the evaluation of AGHD in the US market. As noted above, our NDA is currently under substantive review
by the FDA with a decision expected imminently. Subject to the successful review and acceptance of our NDA, we expect to
make Macrilen™ available by prescription in the US as soon as commercially practicable following final regulatory approval.